igeahub.com
Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis - IgeaHub
Feb 17, 2017 Celgene Corporation has announced that its phase III SUNBEAM trial that evaluates the safety and efficacy of ozanimod, an investigational